Successful treatment of disseminated mucormycosis with a combination of liposomal amphotericin B and posaconazole in a patient with acute myeloid leukaemia

Mycoses

Volumn 49, Issue SUPPL. 1, 2006, Pages 27-30

  Rickerts, V ^a   Atta, J ^a   Herrmann, S ^a   Jacobi, V ^a   Lambrecht, E ^a   Bialek, R ^b   Just Nubling G ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Antifungal combination; Liposomal amphotericin B; Mucormycosis; Posaconazole

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; POSACONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BRONCHUS BIOPSY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MORTALITY; MUCORMYCOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THORAX RADIOGRAPHY;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, MYELOID, ACUTE; LIPOSOMES; MIDDLE AGED; MUCORMYCOSIS; RHIZOMUCOR; TREATMENT OUTCOME; TRIAZOLES;

EID: 33748580665     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01299.x     Document Type: Article

References (16)

1. Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350-60.
2. Spellberg B, Edwards J, Jr , Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005; 18: 556-69.
3. Gleissner B, Schilling A, Anagnostopoulos I, Siehl I, Thiel E. Improved outcome of zygomycosis in patients with hematological diseases. Leuk Lymphoma 2004; 45: 1351-60.
4. Bialek R, Konrad F, Kern J et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 2005; 58: 1180-4.
5. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE, Jr. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with rhizopus oryzae. Antimicrob Agents Chemother 2003; 47: 3343-4.
6. Dannaoui E, Meletiadis J, Mouton JW, Meis JFGM, Verweij PE, the EN. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 2003; 51: 45-52.
7. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In Vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-2.
8. Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: 634-53.
9. Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In Vivo activity of posaconazole against mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2.
10. Dannaoui E, Meis JFGM, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob Agents Chemother 2003; 47: 3647-50.
11. Greenberg RN, Mullane K, van Burik J-AH et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-33.
12. Rickerts V, Just-Nubling G, Konrad F et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 2006; 25: 8-13.
13. Barchiesi F, Spreghini E, Schimizzi AM et al. Posaconazole and amphotericin B combination therapy against cryptococcus neoformans infection. Antimicrob Agents Chemother 2004; 48: 3312-6.
14. Najvar LK, Cacciapuoti A, Hernandez S et al. Activity of posaconazole combined with amphotericin B against aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758-64.
15. Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against candida albicans in vivo. Antimicrob Agents Chemother 2005; 49: 638-42.
16. Lewis RE, Kantoyiannis DP, Najvar LK, Graybill JR, Cacciapuoti AF. Challenges in designing animal studies to detect antagonism of polyene activity. Antimicrob Agents Chemother 2004; 48: 3211-2.